<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Almanac of Clinical Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Almanac of Clinical Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Альманах клинической медицины</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-0505</issn><issn publication-format="electronic">2587-9294</issn><publisher><publisher-name xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17312</article-id><article-id pub-id-type="doi">10.18786/2072-0505-2024-52-031</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical and neurological specifics of the vertebrogenic lumbosacral radiculopathy course in the patients with RS1143627 polymorphism of the <italic>IL-1β</italic> gene</article-title><trans-title-group xml:lang="ru"><trans-title>Клинико-неврологические особенности течения вертеброгенной пояснично-крестцовой радикулопатии у пациентов с полиморфизмом RS1143627 гена <italic>IL-1β</italic></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7477-8857</contrib-id><name-alternatives><name xml:lang="en"><surname>Statinova</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Статинова</surname><given-names>Елена Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>МD, PhD, Professor, Head of the Department of Neurology and Medical Genetics</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, зав. кафедрой неврологии и медицинской генетики</p></bio><email>sneuro@inbax.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fominova</surname><given-names>Natalya V.</given-names></name><name xml:lang="ru"><surname>Фоминова</surname><given-names>Наталья Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Associate Professor of the Department of Neurology and Medical Genetics</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент кафедры неврологии и медицинской генетики</p></bio><email>natali7370@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7987-4091</contrib-id><name-alternatives><name xml:lang="en"><surname>Kishenya</surname><given-names>Maria S.</given-names></name><name xml:lang="ru"><surname>Кишеня</surname><given-names>Мария Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Senior Research Fellow, Head of the Department of Molecular Genetic Testing, Central Scientific Research Laboratory</p></bio><bio xml:lang="ru"><p>канд. мед. наук, ст. науч. сотр., начальник отдела молекулярно-генетических исследований Центральной научно-исследовательской лаборатории</p></bio><email>maria.kishenya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">M. Gorky Donetsk State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Донецкий государственный медицинский университет имени М. Горького» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-11-24" publication-format="electronic"><day>24</day><month>11</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-12-16" publication-format="electronic"><day>16</day><month>12</month><year>2024</year></pub-date><volume>52</volume><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>307</fpage><lpage>314</lpage><history><date date-type="received" iso-8601-date="2024-08-05"><day>05</day><month>08</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-11-06"><day>06</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Statinova E.A., Fominova N.V., Kishenya M.S.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Статинова Е.А., Фоминова Н.В., Кишеня М.С.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Statinova E.A., Fominova N.V., Kishenya M.S.</copyright-holder><copyright-holder xml:lang="ru">Статинова Е.А., Фоминова Н.В., Кишеня М.С.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://almclinmed.ru/jour/article/view/17312">https://almclinmed.ru/jour/article/view/17312</self-uri><abstract xml:lang="en"><p><bold>Rationale:</bold> Vertebrogenic lumbosacral radiculopathy (VLSRP) is a consequence of exposure to physical exertion, back injuries, and smoking. Genetic polymorphism of the cytokine<italic> </italic>IL-1β contributes to the progression of VLSRP due to its increased production in certain genetic variants.</p> <p><bold>Aim:</bold> To establish an association between the rs1143627 polymorphism of the <italic>IL-1β</italic> gene with VLSRP, as well as with clinical and neurological specifics of VLSRP during its treatment.</p> <p><bold>Methods: </bold>The study involved 121 patients with VLSRP aged 22 to 66 years (median, 41 [35; 49] years; men, 110 (90.91%)), treated in the in-patient Department of Neurology from January 2023 to February 2024, and 100 age- and gender compatible healthy subjects. Based on the results of clinical and neurological assessments, the indices of the Digital Rating Scale, Oswestry and Roland-Morris questionnaires were determined. The rs1143627 polymorphism was identified by real-time polymerase chain reaction (IQ5 amplifier (Bio-Rad, USA)) with the SNP-express (IL-1β-31C/T) test system (Litech, Russia).</p> <p><bold>Results:</bold> VLSRP was associated with the distribution of alleles (χ<sup>2</sup> = 3.93; p = 0.049) and genotypes according to the dominant model (χ<sup>2</sup> = 4.7; p = 0.032) of the rs1143627 polymorphism of the <italic>IL-1β</italic> gene. The minor T allele increased the odds ratio for VLSRP (OR 1.51; 95% CI 1.004–2.26) in the dominant model; the sum of CC + CT genotypes was also associated with increased VPSRP odds ratio (OR 1.814; 95% CI 1.056–3.115). The DRS scores under treatment showed the significant predominance of pain in the T (CT + TT) allele carriers (p &lt; 0.001). As assessed by the Oswestry and Roland-Morris questionnaires, the minor T allele in CT + TT genotypes demonstrated prevailing everyday life activities and less effective results after a treatment course (p &lt; 0.001). In the study subjects of ≤ 41 years of age, the multiplicative model showed a higher risk of VLSRP with the minor T allele by 1.8-fold (OR 1.80; 95% CI 1.02–3.19). In the dominant model, the sum of genotypes with the minor T allele (CT + TT) was associated with a 2.23-fold higher risk of VLSRP (OR 2.23; 95% CI 1.05–4.72).</p> <p><bold>Conclusions:</bold> We were able to find the association between the rs1143627 polymorphism of the <italic>IL-1β</italic> gene with VLSRP, with a higher risk of the disease in the patients of ≤ 41 years of age, higher DRS, Oswestry, and Roland-Morris questionnaire scores, which was related to the presence of a minor T allele and CT + TT genotypes.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность.</bold> Вертеброгенная поясничнокрестцовая радикулопатия (ВПКРП) развивается вследствие воздействия физических нагрузок, травм спины, курения. Наличие генетического полиморфизма цитокина интерлейкина-1β (IL-1β) способствует прогрессированию ВПКРП за счет его увеличенной продукции при определенных генетических вариантах.</p> <p><bold>Цель</bold> – определить ассоциацию полиморфизма rs1143627 гена <italic>IL-1β</italic> с ВПКРП, а также связь с клинико-неврологическими особенностями ВПКРП на фоне лечения.</p> <p><bold>Материал и методы.</bold> Обследован 121 пациент с ВПКРП в возрасте от 22 до 66 лет (медиана – 41 [35; 49] год; мужчин – 110 (90,91%)), проходивший лечение в неврологическом отделении стационара в период с января 2023 по февраль 2024 г., и 100 практически здоровых человек, сопоставимых по полу и возрасту. По результатам клинико-неврологических исследований определяли показатели цифровой рейтинговой шкалы (ЦРШ), опросников Освестри, Роланда – Морриса. Полиморфизм rs1143627 выявляли методом полимеразной цепной реакции в режиме реального времени (амплификатор IQ5 (Bio-Rad, США)) с помощью тест-системы SNP-экспресс (IL-1β-31С/Т) (Литех, Россия).</p> <p><bold>Результаты.</bold> Развитие ВПКРП было связано с распределением аллелей (χ<sup>2</sup> = 3,93; р = 0,049) и генотипов по доминантной модели (χ<sup>2</sup> = 4,7; р = 0,032) полиморфизма rs1143627 гена <italic>IL-1β</italic>. Минорная аллель Т увеличивала шансы возникновения ВПКРП (отношение шансов (ОШ) 1,51; 95% доверительный интервал (ДИ) 1,004–2,26) в доминантной модели, сумма генотипов СС + СТ также увеличивала шансы развития заболевания (ОШ 1,814; 95% ДИ 1,056–3,115). Показатели ЦРШ на фоне лечения свидетельствовали о существенном преобладании боли у носителей аллели Т (СТ + ТТ) (р &lt; 0,001). При оценке опросников Освестри и Роланда – Морриса наличие минорной Т-аллели в генотипах СТ + ТТ демонстрировало значимое преобладание нарушений жизнедеятельности и менее эффективные результаты после курса лечения (р &lt; 0,001). У лиц в возрасте ≤ 41 года в мультипликативной модели минорная аллель Т повышала риск развития ВПКРП в 1,8 раза (ОШ 1,80; 95% ДИ 1,02–3,18) и в доминантной модели сумма генотипов с минорной аллелью Т (СТ + ТТ) повышала риск развития ВПКРП в 2,23 раза (ОШ 2,23; 95% ДИ 1,05–4,72).</p> <p><bold>Заключение.</bold> Установлена ассоциация полиморфизма rs1143627 гена <italic>IL-1β</italic> с развитием ВПКРП, более высоким риском заболевания у пациентов ≤ 41 года, более выраженными показателями ЦРШ, опросников Освестри и Роланда – Морриса, что связано с наличием минорной аллели Т и генотипов СТ + ТТ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>vertebrogenic lumbosacral radiculopathy</kwd><kwd>Digital Rating Scale</kwd><kwd>Oswestry questionnaire</kwd><kwd>rs1143627 polymorphism</kwd><kwd>IL-1β gene</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>вертеброгенная пояснично-крестцовая радикулопатия</kwd><kwd>цифровая рейтинговая шкала</kwd><kwd>шкала Освестри</kwd><kwd>полиморфизм rs1143627</kwd><kwd>ген IL-1β</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Knezevic NN, Candido KD, Vlaeyen JWS, Van Zundert J, Cohen SP. Low back pain. Lancet. 2021;398(10294):78–92. doi: 10.1016/S0140-6736(21)00733-9.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Schumann B, Bolm-Audorff U, Bergmann A, Ellegast R, Elsner G, Grifka J, Haerting J, Jäger M, Michaelis M, Seidler A. Lifestyle factors and lumbar disc disease: results of a German multi-center case-control study (EPILIFT). Arthritis Res Ther. 2010;12(5):R193. doi: 10.1186/ar3164.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kim KS, Yoon ST, Park JS, Li J, Park MS, Hutton WC. Inhibition of proteoglycan and type II collagen synthesis of disc nucleus cells by nicotine. J Neurosurg. 2003;99(3 Suppl):291–297. doi: 10.3171/spi.2003.99.3.0291.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Qi L, Luo L, Meng X, Zhang J, Yu T, Nie X, Liu Q. Risk factors for lumbar disc herniation in adolescents and young adults: A case-control study. Front Surg. 2023;9:1009568. doi: 10.3389/fsurg.2022.1009568.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Zhang Y, Sun Z, Liu J, Guo X. Advances in susceptibility genetics of intervertebral degenerative disc disease. Int J Biol Sci. 2008;4(5):283–290. doi: 10.7150/ijbs.4.283.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kales SN, Linos A, Chatzis C, Sai Y, Halla M, Nasioulas G, Christiani DC. The role of collagen IX tryptophan polymorphisms in symptomatic intervertebral disc disease in Southern European patients. Spine (Phila Pa 1976). 2004;29(11):1266–1270. doi: 10.1097/00007632-200406010-00017.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Jiang L, Wang C, Ye Z, Hu Q. A novel missense COL9A3 variant in a pedigree with multiple lumbar disc herniation. J Orthop Surg Res. 2024;19(1):19. doi: 10.1186/s13018-023-04481-2.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Solovieva S, Kouhia S, Leino-Arjas P, Ala-Kokko L, Luoma K, Raininko R, Saarela J, Riihimäki H. Interleukin 1 polymorphisms and intervertebral disc degeneration. Epidemiology. 2004;15(5):626–633. doi: 10.1097/01.ede.0000135179.04563.35.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lin WP, Lin JH, Chen XW, Wu CY, Zhang LQ, Huang ZD, Lai JM. Interleukin-10 promoter polymorphisms associated with susceptibility to lumbar disc degeneration in a Chinese cohort. Genet Mol Res. 2011;10(3):1719–1727. doi: 10.4238/vol10-3gmr1283.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Jacobsen HE, Khan AN, Levine ME, Filippi CG, Chahine NO. Severity of intervertebral disc herniation regulates cytokine and chemokine levels in patients with chronic radicular back pain. Osteoarthritis Cartilage. 2020;28(10):1341–1350. doi: 10.1016/j.joca.2020.06.009.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther. 2005;7(4):R732–R745. doi: 10.1186/ar1732.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Zhang C, Gullbrand SE, Schaer TP, Lau YK, Jiang Z, Dodge GR, Elliott DM, Mauck RL, Malhotra NR, Smith LJ. Inflammatory cytokine and catabolic enzyme expression in a goat model of intervertebral disc degeneration. J Orthop Res. 2020;38(11):2521–2531. doi: 10.1002/jor.24639.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Li H, Wang X, Pan H, Xiao C, Wang C, Guo S, Long L, Shi H, Chen H, Li S. The mechanisms and functions of IL-1β in intervertebral disc degeneration. Exp Gerontol. 2023;177:112181. doi: 10.1016/j.exger.2023.112181.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wang Y, Che M, Xin J, Zheng Z, Li J, Zhang S. The role of IL-1β and TNF-α in intervertebral disc degeneration. Biomed Pharmacother. 2020;131:110660. doi: 10.1016/j.biopha.2020.110660.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Li Z, Yang H, Hai Y, Cheng Y. Regulatory effect of inflammatory mediators in intervertebral disc degeneration. Mediators Inflamm. 2023;2023:6210885. doi: 10.1155/2023/6210885.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Biczo A, Bereczki F, Koch K, Varga PP; Genodisc Consortium; Lazary A. Genetic variants of interleukin 1B and 6 are associated with clinical outcome of surgically treated lumbar degenerative disc disease. BMC Musculoskelet Disord. 2022;23(1):774. doi: 10.1186/s12891-022-05711-0.</mixed-citation></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Rozhkov DO, Zinovyeva OE, Nosovsky AM, Parfenov VA. [Treatment of patients with chronic nonspecific lumbalgia with various pain triggers]. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(4):72–77. Russian. doi: 10.17116/jnevro202312304172</mixed-citation><mixed-citation xml:lang="ru">Рожков ДО, Зиновьева ОЕ, Носовский АМ, Парфенов ВА. Лечение пациенток с хронической неспецифической люмбалгией, связанной с различными болевыми триггерами. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(4):72–77. doi: 10.17116/jnevro202312304172.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><mixed-citation>Rasmussen-Barr E, Held U, Grooten WJA, Roelofs PDDM, Koes BW, van Tulder MW, Wertli MM. Nonsteroidal anti-inflammatory drugs for sciatica: an updated Cochrane review. Spine (Phila Pa 1976). 2017;42(8):586–594. doi: 10.1097/BRS.0000000000002092.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kuritzky L, Samraj GP. Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. J Pain Res. 2012;5:579–590. doi: 10.2147/JPR.S6775.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928–1929. doi: 10.1093/bioinformatics/btl268.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Moen A, Schistad EI, Rygh LJ, Røe C, Gjerstad J. Role of IL1A rs1800587, IL1B rs1143627 and IL1RN rs2234677 genotype regarding development of chronic lumbar radicular pain; a prospective one-year study. PLoS One. 2014;9(9):e107301. doi: 10.1371/journal.pone.0107301.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Swamy G, Salo P, Duncan N, Jirik F, Matyas J. IL-1Ra deficiency accelerates intervertebral disc degeneration in C57BL6J mice. JOR Spine. 2022;5(2):e1201. doi: 10.1002/jsp2.1201.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Shnayder NA, Ashhotov AV, Trefilova VV, Nurgaliev ZA, Novitsky MA, Vaiman EE, Petrova MM, Nasyrova RF. Cytokine imbalance as a biomarker of intervertebral disk degeneration. Int J Mol Sci. 2023;24(3):2360. doi: 10.3390/ijms24032360.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Phillips KL, Jordan-Mahy N, Nicklin MJ, Le Maitre CL. Interleukin-1 receptor antagonist deficient mice provide insights into pathogenesis of human intervertebral disc degeneration. Ann Rheum Dis. 2013;72(11):1860–1867. doi: 10.1136/annrheumdis-2012-202266.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Paz Aparicio J, Fernández Bances I, López-Anglada Fernández E, Montes AH, Paz Aparicio A, Pena Vázquez J, Ramos García S, Antón García S, López Fernández P, Valle-Garay E, Asensi V. The IL-1β (+3953 T/C) gene polymorphism associates to symptomatic lumbar disc herniation. Eur Spine J. 2011;20 Suppl 3(Suppl 3):383–389. doi: 10.1007/s00586-011-1915-2.</mixed-citation></ref></ref-list></back></article>
